weight loss drugs

Eli Lilly eyes $2 trillion valuation from weight-loss drugs, Alzheimer's breakthroughs, and AI-powered R&D following recent market pullback.

Novo Nordisk's Q1 sales of $15.17B beat estimates, with Wegovy pill reaching 2M prescriptions. Company raised 2026 guidance to $42.39-$46.24B; shares surged 7.11%.

Eli Lilly's weight loss drugs deliver explosive growth with Mounjaro up 125% and Zepbound up 80%. New oral drug Foundayo already serves 20,000 patients.

Eli Lilly beat Q1 earnings expectations and raised full-year guidance, driven by blockbuster demand for weight-loss drugs Mounjaro and Zepbound.

Morgan Stanley analyst targets $1,327 for Eli Lilly, citing $45B weight-loss drug sales potential by 2030, implying 52% upside from current $870 levels.

Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.

Eli Lilly shows 43% revenue growth and 51% EPS growth, backed by weight-loss drug leadership and $7B cancer acquisition. Forward P/E of 40 remains below historical average.

Novo Nordisk's 72% crash from peaks sparks debate: value trap or buying opportunity amid GLP-1 market competition from Eli Lilly.

DexCom benefits from GLP-1 weight-loss drug adoption regardless of pharmaceutical winner, leveraging competitive moats in CGM technology and ecosystem integration.

PepsiCo and Lowe's, both Dividend Kings with 50+ years of consecutive dividend increases, offer attractive passive income opportunities despite current market skepticism and valuation discounts.

Eli Lilly acquires Centessa Pharmaceuticals for $6.3B, gaining neuroscience assets. Stock rises on strong financial footing from weight-loss drug success.

Eli Lilly controls 60% of U.S. weight loss market with $11B+ quarterly revenue. Pipeline drug retatrutide showing 28% weight reduction could extend lead over Novo Nordisk.

Eli Lilly reaches $1 trillion valuation while outperforming Novo Nordisk over three years, driven by superior weight-loss drug efficacy and robust pipeline strength.

Eli Lilly's Mounjaro loses market share in India to cheaper GLP-1 generics; sales fell 16% in March. FDA approves Lilly's oral GLP-1 Foundayo.

Eli Lilly bets on AI-driven drug discovery alongside its $11B weight loss drug franchise, partnering with Nvidia and Insilico Medicine to build next-generation blockbusters.

Regeneron's 35% recovery masks limited multimillionaire potential at $79B valuation, positioning shares for S&P-matching returns rather than exceptional gains.

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.

Eli Lilly awaits April 10 FDA decision on oral weight loss drug orforglipron, amid $11B quarterly sales from current portfolio. Approval could catalyze gains, but long-term fundamentals matter more than short-term decisions.

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.